Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer
Nabeel M. Bardeesy, Kuang‐Hung Cheng, Justin H. Berger et al. · Genes & Development · 2006
SMAD4 is inactivated in the majority of pancreatic ductal adenocarcinomas (PDAC) with concurrent mutational inactivation of the INK4A/ARF tumor suppressor locus and activation of the KRAS oncogene. Here, using genetically engineered mice, we determined the impact of SMAD4 deficiency on the development of the pancreas and on the initiation and/or progression of PDAC-alone or in combination with PDAC--relevant mutations. Selective SMAD4 deletion in the pancreatic epithelium had no discernable impact on pancreatic development or physiology. However, when combined with the activated KRAS(G12D) allele, SMAD4 deficiency enabled rapid progression of KRAS(G12D)-initiated neoplasms. While KRAS(G12D) alone elicited premalignant pancreatic intraepithelial neoplasia (PanIN) that progressed slowly to carcinoma, the combination of KRAS(G12D) and SMAD4 deficiency resulted in the rapid development of tumors resembling intraductal papillary mucinous neoplasia (IPMN), a precursor to PDAC in humans. SMAD4 deficiency also accelerated PDAC development of KRAS(G12D) INK4A/ARF heterozygous mice and altered the tumor phenotype; while tumors with intact SMAD4 frequently exhibited epithelial-to-mesenchymal transition (EMT), PDAC null for SMAD4 retained a differentiated histopathology with increased expression of epithelial markers. SMAD4 status in PDAC cell lines was associated with differential responses to transforming growth factor-beta (TGF-beta) in vitro with a subset of SMAD4 wild-type lines showing prominent TGF-beta-induced proliferation and migration. These results provide genetic confirmation that SMAD4 is a PDAC tumor suppressor, functioning to block the progression of KRAS(G12D)-initiated neoplasms, whereas in a subset of advanced tumors, intact SMAD4 facilitates EMT and TGF-beta-dependent growth.
Cited by 673 works. doi:10.1101/gad.1478706 Open-access PDF
Authors
- Nabeel M. Bardeesy
- Kuang‐Hung Cheng
- Justin H. Berger
- Gerald C. Chu
- Jessica C. Pahler
- Peter Olson
- Aram F. Hezel
- James W. Horner
- Gregory Yves Lauwers
- Douglas Hanahan
- Ronald Anthony DePinho
References
- Pancreatic Cancer
- DPC4 , A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1
- Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
- Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice
- Pancreatic cancer
- High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP
- Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors
- Mutations in the SMAD4/DPC4 Gene in Juvenile Polyposis
- Genetics and biology of pancreatic ductal adenocarcinoma
- TGF-β and epithelial-to-mesenchymal transitions